KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Non Operating Income (2016 - 2025)

Arbutus Biopharma's Non Operating Income history spans 11 years, with the latest figure at $917000.0 for Q3 2025.

  • For Q3 2025, Non Operating Income fell 46.78% year-over-year to $917000.0; the TTM value through Sep 2025 reached $4.5 million, down 29.64%, while the annual FY2024 figure was $6.4 million, 21.79% up from the prior year.
  • Non Operating Income for Q3 2025 was $917000.0 at Arbutus Biopharma, down from $1.0 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $1.8 million in Q2 2024 and bottomed at -$750000.0 in Q3 2021.
  • The 5-year median for Non Operating Income is $1.0 million (2025), against an average of $657736.8.
  • The largest annual shift saw Non Operating Income surged 1655.42% in 2023 before it crashed 46.78% in 2025.
  • A 5-year view of Non Operating Income shows it stood at -$525000.0 in 2021, then soared by 220.0% to $630000.0 in 2022, then soared by 127.78% to $1.4 million in 2023, then dropped by 2.37% to $1.4 million in 2024, then crashed by 34.55% to $917000.0 in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Non Operating Income are $917000.0 (Q3 2025), $1.0 million (Q2 2025), and $1.2 million (Q1 2025).